← Leaderboards
Eric Thompson
Duke University
$1,565,765
Attributed
$2,261,863
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $989.3K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$1,392,196 · 1
NIH$869,667 · 3
By mechanism
R01$1,945,363 · 2
R03$316,500 · 2
Top collaborators
- Daniel Bryce Landi3 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Rod Zalutsky$18,420,913
- Darell D Bigner$25,397,506
- Dorothy A Sipkins$8,543,606
- David M. Ashley$7,073,119
- Henry S. Friedman$12,588,060
Others in their field
Other Emerging Leaders on “Medulloblastoma”
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Paul Northcott · St. Jude Children'S Research Hospital$6,615,541
- Rachael W Sirianni · Arizona State University-Tempe Campus$5,945,559
- Catherine T Flores · University Of Florida$3,745,308
- Giedre Krenciute · St. Jude Children'S Research Hospital$2,210,532
- Lukas Chavez · University Of California, San Diego$1,914,963
Research focus
MedulloblastomaChemotherapyChildChildhood Brain NeoplasmPhase I Clinical TrialsDiagnosisEpendymomaRecurrenceBrainTumorQuality Of LifeSubgroupMalignant Childhood NeoplasmPilot ProjectsAgedAntigen-Specific T CellsAntigensChemotherapy And/Or RadiationChildhood GliomaBrain NeoplasmsAntigen PresentationBiopsyBrain TissueCessation Of Life
Grant awards (8)
Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)$553,167
R01 · FY2025 · CA · contact PI
Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma$358,401
R01 · FY2025 · FD
Expanding CMV peptide vaccine with novel combinations and pathologies$77,750
R03 · FY2025 · NS · contact PI
Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma$336,734
R01 · FY2024 · FD
Expanding CMV peptide vaccine with novel combinations and pathologies$77,750
R03 · FY2024 · NS · contact PI
Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma$697,061
R01 · FY2021 · FD
Unraveling the Role of ABL 1 and 2 as Drivers of Medulloblastoma Leptomeningeal Metastases$80,500
R03 · FY2021 · NS · contact PI
Unraveling the Role of ABL 1 and 2 as Drivers of Medulloblastoma Leptomeningeal Metastases$80,500
R03 · FY2020 · NS · contact PI